vs
ASCENT INDUSTRIES CO.（ACNT）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
ASCENT INDUSTRIES CO.的季度营收约是Protalix BioTherapeutics, Inc.的1.3倍（$11.9M vs $9.1M），ASCENT INDUSTRIES CO.净利率更高（-8.8% vs -60.3%，领先51.6%），ASCENT INDUSTRIES CO.同比增速更快（13.3% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $-196.0K），过去两年Protalix BioTherapeutics, Inc.的营收复合增速更高（-6.7% vs -34.9%）
阿森特工业（股票代码ACNT）前身为拆分自探索控股公司的独立上市媒体企业阿森特传媒，后转型为公开上市控股公司，核心子公司为莫尼特罗尼克斯，主营依托子公司开展安防相关业务运营。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
ACNT vs PLX — 直观对比
营收规模更大
ACNT
是对方的1.3倍
$9.1M
营收增速更快
ACNT
高出63.3%
-49.9%
净利率更高
ACNT
高出51.6%
-60.3%
自由现金流更多
PLX
多$1.8M
$-196.0K
两年增速更快
PLX
近两年复合增速
-34.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.9M | $9.1M |
| 净利润 | $-1.0M | $-5.5M |
| 毛利率 | 14.6% | 49.4% |
| 营业利润率 | -21.0% | -51.1% |
| 净利率 | -8.8% | -60.3% |
| 营收同比 | 13.3% | -49.9% |
| 净利润同比 | -1.2% | -184.8% |
| 每股收益（稀释后） | $-0.11 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACNTPLX
| Q4 25 | $11.9M | $9.1M | ||
| Q3 25 | $19.7M | $17.9M | ||
| Q2 25 | $18.7M | $15.7M | ||
| Q1 25 | $24.7M | $10.1M | ||
| Q4 24 | $10.5M | $18.2M | ||
| Q3 24 | $20.9M | $18.0M | ||
| Q2 24 | $21.5M | $13.5M | ||
| Q1 24 | $28.0M | — |
净利润ACNTPLX
| Q4 25 | $-1.0M | $-5.5M | ||
| Q3 25 | $-2.1M | $2.4M | ||
| Q2 25 | $6.3M | $164.0K | ||
| Q1 25 | $-2.3M | $-3.6M | ||
| Q4 24 | $-1.0M | $6.5M | ||
| Q3 24 | $-6.2M | $3.2M | ||
| Q2 24 | $-926.0K | $-2.2M | ||
| Q1 24 | $-5.5M | — |
毛利率ACNTPLX
| Q4 25 | 14.6% | 49.4% | ||
| Q3 25 | 29.7% | 53.4% | ||
| Q2 25 | 26.1% | 62.5% | ||
| Q1 25 | 19.3% | 19.1% | ||
| Q4 24 | 24.3% | 78.7% | ||
| Q3 24 | 14.4% | 53.4% | ||
| Q2 24 | 13.1% | 29.8% | ||
| Q1 24 | 8.3% | — |
营业利润率ACNTPLX
| Q4 25 | -21.0% | -51.1% | ||
| Q3 25 | -4.1% | 11.9% | ||
| Q2 25 | -14.4% | 7.5% | ||
| Q1 25 | -4.2% | -41.0% | ||
| Q4 24 | -25.4% | 39.6% | ||
| Q3 24 | -9.4% | 22.2% | ||
| Q2 24 | -8.6% | -18.0% | ||
| Q1 24 | -15.5% | — |
净利率ACNTPLX
| Q4 25 | -8.8% | -60.3% | ||
| Q3 25 | -10.6% | 13.2% | ||
| Q2 25 | 33.7% | 1.0% | ||
| Q1 25 | -9.3% | -35.8% | ||
| Q4 24 | -9.8% | 35.6% | ||
| Q3 24 | -29.5% | 18.0% | ||
| Q2 24 | -4.3% | -16.4% | ||
| Q1 24 | -19.7% | — |
每股收益（稀释后）ACNTPLX
| Q4 25 | $-0.11 | $-0.06 | ||
| Q3 25 | $-0.22 | $0.03 | ||
| Q2 25 | $0.65 | $0.00 | ||
| Q1 25 | $-0.23 | $-0.05 | ||
| Q4 24 | $-0.11 | $0.10 | ||
| Q3 24 | $-0.61 | $0.03 | ||
| Q2 24 | $-0.09 | $-0.03 | ||
| Q1 24 | $-0.54 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.6M | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $87.0M | $48.2M |
| 总资产 | $111.9M | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACNTPLX
| Q4 25 | $57.6M | $14.7M | ||
| Q3 25 | $58.0M | $13.6M | ||
| Q2 25 | $60.5M | $17.9M | ||
| Q1 25 | $14.3M | $19.5M | ||
| Q4 24 | $16.1M | $19.8M | ||
| Q3 24 | $8.5M | $27.4M | ||
| Q2 24 | $3.6M | $23.4M | ||
| Q1 24 | $1.3M | — |
总债务ACNTPLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACNTPLX
| Q4 25 | $87.0M | $48.2M | ||
| Q3 25 | $87.1M | $52.9M | ||
| Q2 25 | $89.7M | $49.9M | ||
| Q1 25 | $91.2M | $45.2M | ||
| Q4 24 | $93.5M | $43.2M | ||
| Q3 24 | $94.7M | $32.4M | ||
| Q2 24 | $101.0M | $28.6M | ||
| Q1 24 | $102.0M | — |
总资产ACNTPLX
| Q4 25 | $111.9M | $82.3M | ||
| Q3 25 | $119.9M | $82.3M | ||
| Q2 25 | $122.6M | $78.5M | ||
| Q1 25 | $152.5M | $73.9M | ||
| Q4 24 | $147.3M | $73.4M | ||
| Q3 24 | $148.6M | $61.6M | ||
| Q2 24 | $158.2M | $91.5M | ||
| Q1 24 | $161.0M | — |
负债/权益比ACNTPLX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $266.0K | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $-196.0K | $1.6M |
| 自由现金流率自由现金流/营收 | -1.7% | 17.8% |
| 资本支出强度资本支出/营收 | 3.9% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-2.1M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流ACNTPLX
| Q4 25 | $266.0K | $2.0M | ||
| Q3 25 | $1.3M | $-3.7M | ||
| Q2 25 | $-1.4M | $-5.2M | ||
| Q1 25 | $-700.0K | $-5.1M | ||
| Q4 24 | $8.8M | $4.0M | ||
| Q3 24 | $3.4M | $4.1M | ||
| Q2 24 | $2.2M | $-3.6M | ||
| Q1 24 | $263.0K | — |
自由现金流ACNTPLX
| Q4 25 | $-196.0K | $1.6M | ||
| Q3 25 | $695.0K | $-4.2M | ||
| Q2 25 | $-1.5M | $-5.7M | ||
| Q1 25 | $-1.0M | $-5.4M | ||
| Q4 24 | $8.4M | $3.6M | ||
| Q3 24 | $3.1M | $4.0M | ||
| Q2 24 | $1.9M | $-3.8M | ||
| Q1 24 | $25.0K | — |
自由现金流率ACNTPLX
| Q4 25 | -1.7% | 17.8% | ||
| Q3 25 | 3.5% | -23.7% | ||
| Q2 25 | -8.3% | -36.2% | ||
| Q1 25 | -4.1% | -53.0% | ||
| Q4 24 | 80.6% | 19.6% | ||
| Q3 24 | 15.1% | 22.4% | ||
| Q2 24 | 9.1% | -28.1% | ||
| Q1 24 | 0.1% | — |
资本支出强度ACNTPLX
| Q4 25 | 3.9% | 4.4% | ||
| Q3 25 | 3.1% | 2.8% | ||
| Q2 25 | 0.8% | 2.8% | ||
| Q1 25 | 1.3% | 3.0% | ||
| Q4 24 | 3.7% | 2.3% | ||
| Q3 24 | 1.3% | 0.5% | ||
| Q2 24 | 1.0% | 1.3% | ||
| Q1 24 | 0.9% | — |
现金转化率ACNTPLX
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | -0.22× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACNT
| Other | $6.1M | 52% |
| Transferred At Point In Time | $5.7M | 48% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
